樺花粉アレルギー(Birch Pollen Allergy)の治療薬パイプライン動向(2015年上半期版)

Global Markets Directが発行した調査報告書(GMDHC6081IDB)
◆英語タイトル:Birch Pollen Allergy - Pipeline Review, H1 2015
◆商品コード:GMDHC6081IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2015年1月22日
◆ページ数:49
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界における樺花粉アレルギー(Birch Pollen Allergy)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・樺花粉アレルギー(Birch Pollen Allergy)の概要
・樺花粉アレルギー(Birch Pollen Allergy)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・樺花粉アレルギー(Birch Pollen Allergy)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・樺花粉アレルギー(Birch Pollen Allergy)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・樺花粉アレルギー(Birch Pollen Allergy)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Birch Pollen Allergy – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Birch Pollen Allergy – Pipeline Review, H1 2015’, provides an overview of the Birch Pollen Allergy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Birch Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Birch Pollen Allergy and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Birch Pollen Allergy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Birch Pollen Allergy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Birch Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Birch Pollen Allergy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Birch Pollen Allergy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Birch Pollen Allergy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Birch Pollen Allergy Overview 6
Therapeutics Development 7
Pipeline Products for Birch Pollen Allergy – Overview 7
Pipeline Products for Birch Pollen Allergy – Comparative Analysis 8
Birch Pollen Allergy – Therapeutics under Development by Companies 9
Birch Pollen Allergy – Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Birch Pollen Allergy – Products under Development by Companies 13
Birch Pollen Allergy – Companies Involved in Therapeutics Development 14
ALK-Abello A/S 14
Allergopharma Joachim Ganzer KG 15
Anergis SA 16
Biomay AG 17
Circassia Pharmaceuticals plc 18
HAL Allergy BV 19
Stallergenes S.A. 20
Birch Pollen Allergy – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
ALK Birch Pollen Vaccine – Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis – Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
AllerT – Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Birch-SPIRE – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
BM-31 – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Drug for Birch Pollen Allergy – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
PL-102 – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
rBet v1 – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
rBet v1-FV – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Birch Pollen Allergy – Recent Pipeline Updates 38
Birch Pollen Allergy – Dormant Projects 40
Birch Pollen Allergy – Discontinued Products 41
Birch Pollen Allergy – Product Development Milestones 42
Featured News & Press Releases 42
Dec 11, 2014: Anergis Starts Phase II Dose Ranging Trial with Birch Pollen Allergy Vaccine AllerT 42
Sep 16, 2014: Anergis Reports Positive Long-Term Clinical Efficacy of Lead Compound AllerT 42
Apr 23, 2014: Anergis Completes Enrolment in the Long-Term Efficacy Trial of Lead Compound AllerT 43
Feb 27, 2014: Phase IIb Results of Anergis´ Lead Compound AllerT to be Presented at 2014 AAAAI Annual Meeting in San Diego 43
Oct 21, 2013: Immunology Data Further Underline the Positive Outcome of a Phase IIb Trial of Anergis’s Birch Pollen Allergy Vaccine AllerT 43
Sep 10, 2013: Anergis Reports Positive Phase IIb Data for Birch Pollen Allergy Vaccine AllerT 44
Jan 23, 2013: Anergis Obtains US Patent For Lead Product AllerT 45
Nov 08, 2012: Long-Term Immunomodulation Induced By Anergis’s COP Allergy Vaccine AllerT Extends To Fourth Year After Treatment 45
Nov 06, 2012: Anergis Starts European Phase IIb Clinical Trial With AllerT In Patients With Allergy To Birch Pollen 46
Jan 24, 2011: Anergis Obtains Core Technology Patent Protection in the US 46
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49

[List of Tables]
Number of Products under Development for Birch Pollen Allergy, H1 2015 7
Number of Products under Development for Birch Pollen Allergy - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Late Stage Development, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Birch Pollen Allergy - Pipeline by ALK-Abello A/S, H1 2015 14
Birch Pollen Allergy - Pipeline by Allergopharma Joachim Ganzer KG, H1 2015 15
Birch Pollen Allergy - Pipeline by Anergis SA, H1 2015 16
Birch Pollen Allergy - Pipeline by Biomay AG, H1 2015 17
Birch Pollen Allergy - Pipeline by Circassia Pharmaceuticals plc, H1 2015 18
Birch Pollen Allergy - Pipeline by HAL Allergy BV, H1 2015 19
Birch Pollen Allergy - Pipeline by Stallergenes S.A., H1 2015 20
Assessment by Monotherapy Products, H1 2015 21
Number of Products by Stage and Target, H1 2015 22
Number of Products by Stage and Route of Administration, H1 2015 24
Number of Products by Stage and Molecule Type, H1 2015 26
Birch Pollen Allergy Therapeutics - Recent Pipeline Updates, H1 2015 38
Birch Pollen Allergy - Dormant Projects, H1 2015 40
Birch Pollen Allergy - Discontinued Products, H1 2015 41

[List of Figures]
Number of Products under Development for Birch Pollen Allergy, H1 2015 7
Number of Products under Development for Birch Pollen Allergy - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Early Stage Products, H1 2015 12
Assessment by Monotherapy Products, H1 2015 21
Number of Products by Top 10 Routes of Administration, H1 2015 23
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 24
Number of Products by Top 10 Molecule Types, H1 2015 25
Number of Products by Stage and Top 10 Molecule Types, H1 2015 26

【掲載企業】

ALK-Abello A/S
Allergopharma Joachim Ganzer KG
Anergis SA
Biomay AG
Circassia Pharmaceuticals plc
HAL Allergy BV
Stallergenes S.A.

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 樺花粉アレルギー(Birch Pollen Allergy)の治療薬パイプライン動向(2015年上半期版)(Birch Pollen Allergy - Pipeline Review, H1 2015)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆